Form 4: Harvard Bioscience Director Awarded 110,000 Restricted Stock Units

Harvard Bioscience Inc. Director Katherine A. Eade was granted 110,000 restricted stock units, aligning her interests with long-term shareholder value.

Summary

• Katherine A. Eade, a Director of Harvard Bioscience Inc. (HBIO), was awarded 110,000 restricted stock units (RSUs) on July 16, 2025.
• These RSUs were granted at a price of $0.00, indicating an equity award rather than a cash purchase.
• The RSUs are scheduled to fully vest on the earlier of the company's next Annual Meeting of Stockholders after July 16, 2025, or July 16, 2026.
• Following this transaction, Katherine A. Eade's total beneficial ownership in Harvard Bioscience Inc. stands at 421,126 shares, which includes the newly awarded 110,000 RSUs and 311,126 previously held common shares.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity award to a director, which is generally positive for aligning interests and retention, without any negative implications. The future vesting schedule provides a clear timeline for the director's continued commitment.

Positives

• The award of restricted stock units to a director aligns management and director interests with long-term shareholder value.
• The grant of 110,000 restricted stock units demonstrates the company's commitment to retaining and incentivizing key leadership.
• Increased beneficial ownership by a director to 421,126 shares signals confidence in the company's future prospects.

Risks

• The value of the restricted stock units is subject to the future performance of Harvard Bioscience Inc.'s common stock price.
• Vesting of the 110,000 restricted stock units is contingent upon the director's continued service until the specified vesting dates (earlier of the next Annual Meeting after July 16, 2025, or July 16, 2026).

Future Outlook

The 110,000 restricted stock units awarded to Director Katherine A. Eade are set to fully vest on the earlier of the company's next Annual Meeting of Stockholders after July 16, 2025, or July 16, 2026, indicating a future commitment and alignment of interests.

Industry Context

The award of restricted stock units to a director is a common practice in the biotechnology and life sciences industry, including companies like Harvard Bioscience, to incentivize long-term commitment and align the interests of directors with those of shareholders. This type of equity compensation is a standard component of corporate governance and executive/director remuneration packages across publicly traded companies.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard compensation practice, comparable to similar equity awards seen at other life science tools and research product companies.
• For instance, companies like Bio-Rad Laboratories (BIO), Agilent Technologies (A), or Thermo Fisher Scientific (TMO) frequently utilize RSU grants as part of their non-employee director compensation programs to foster long-term alignment and retention.
• The specific amount of 110,000 units would need to be evaluated against the company's market capitalization, the director's overall compensation package, and peer group practices to determine if it is above, below, or in line with industry averages, but the mechanism itself is standard.

Corporate Governance

Related Party Transactions

• The award of 110,000 restricted stock units to Katherine A. Eade, a Director of Harvard Bioscience Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The award aligns the director's interests with shareholders, potentially fostering better long-term decision-making and increasing insider ownership.

Next Steps

• The 110,000 restricted stock units will vest on the earlier of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, or July 16, 2026.

Key Dates

Recommendation

Keywords

Harvard Bioscience, HBIO, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Ownership, Equity Award, Corporate Governance, Stock Vesting